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Abstract
Benzodiazepines are commonly used as the first line treatment for adults diagnosed with
Generalized Anxiety Disorder (GAD) despite clinical guidelines that recommend otherwise. This
can lead to misuse, abuse, addiction, and dependence. To de-escalate use of benzodiazepines as
first-line treatment, this DNP Project seeks to reinforce use of evidence-based practice via a
reminder card. The guideline compliance program was assessed by chart review to determine
impact on GAD-7 scores and benzodiazepine prescriptions. Total of 69 patients’ charts were
audited by six prescribers, over the period of eight weeks, to determine if outcomes were met.
When analyzed pre and post intervention on GAD-7 scores, a paired sample t-test demonstrated
a p -value of <0.001 which indicated that statistical significance was met. Reinforcement of
clinical guidelines via a reminder card resulted in reduction scored on GAD-7 and number of the
benzodiazepine prescriptions. All patients (N=69) were offered the opportunity to de-escalate
benzodiazepine use by decreasing doses, alternative medications, psychotherapy or were
prescribed medications according to guidelines that promoted decrease in benzodiazepine use.
Keywords: GAD, benzodiazepines, de-escalation, abuse, misuse
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Introduction
Benzodiazepines are beneficial class of drugs in treating anxiety. However, there are
trends indicating a significant public health problem related to benzodiazepines misuse. For
instance, Maust et al. (2020) noted that 30.6 million adults, which accounts for 12.6% of the
entire population used benzodiazepine. It is estimated that 25.3 million (10.4%) adults were
taking it as prescribed, while 5.3 million (2.2%) adults were misusing the medication. Further,
the highest misuse (5.2%) was among persons aged 18 to 25 years old. This public health
challenge is heightened by the fact that abuse, misuse and dependent on stimulants and opioids is
significantly associated with benzodiazepine misuse. Benzodiazepines are most accessed without
a prescription from a friend or family member. This issue is further exacerbated by the absence
of a collective consensus among medical experts on the diagnostic criterion which should be
satisfied to warrant a benzodiazepine prescription (Silberman et al., 2021).
The federal government has taken several measures to address drug abuse. For instance,
according to the Drug Enforcement Agency (2020), the federal government enacted the
Controlled Substances Act (CSA) which regulates production and distribution of the substances’
accepted medical use, potential for abuse, and safety or dependence liability. However,
implementing this act and other measures by the Department of Health and Human Services
(HHS) has not been effective. This can partly be attributed to insufficient data on drug utilization
behaviors and problems associated with recommending relatively high doses of benzodiazepines
has also impeded efforts to appropriately conduct comparative drug consumption within the
United States (Lembke et al., 2018).
According to Samardzic and Svob Strac (2016), benzodiazepine abuse is associated with
physical effects such as poor coordination, loss of visuo-spatial ability, irritability, sleep
disturbances, and continual drowsiness. Extreme cases of benzodiazepine abuse may also result
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in an emergency room (ER) visit and even death. Prolonged use of benzodiazepine among
persons with anxiety and related disorder may exacerbate health conditions by leading to
increased anxiety (Hayhoe & Lee-Davey, 2018). This reinforces the need to de-escalate
benzodiazepine use.
De-escalating the use of benzodiazepines for adults is crucial in concerted health
promotion initiatives to promote the appropriate use of the medication, prevent harm from abuse,
and improve patient outcomes (Suss & Oldani 2020). Healthcare providers particularly
pharmacist, nurses and physicians play a significant role in promoting proper use of and in deescalation among patients with anxiety who have misused the drug (Platt et al., 2021). This is
achieved by implementing evidenced based practice guidelines that will reduce potential for
benzodiazepine misuse and abuse. In this regard, this project aims to remind providers to offer
de-escalation where appropriate and reduce escalation by following treatment recommendations.
Background
According to the DSM-V (2013) guidelines, Generalized Anxiety Disorder (GAD) is
classified as excessive anxiety and worrying that has occurred for a minimum of six months
relating to activities of daily living. The anxiety presents with symptoms equivalent to restless
leg, fatigue, trouble concentrating, irritability, disturbed sleeping, and muscle tension (Simon et
al., 2021). Health providers are likely to find it challenging to diagnose GAD accurately.
Undoubtedly, this created the need for reliable, efficient, and exhaustive screening tools. One
such screening tool is the Generalized Anxiety Disorder scale-7 (GAD-7); a 7-item diagnostic
tool validated in the general population and primary care settings (Sapra et al., 2020). There are
also other multiple scales for screening GAD, including Hamiliton Anxiety Scale (HAM-A),
Covi Anxiety Scale, Hospital Anxiety and Depression Scale (HADS), and State-Trait Anxiety
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Inventory (STAI), among others (Sapra et al., 2020). After patients are identified to have GAD
using some of these screening tools, health providers usually go for thyroid function tests before
prescribing any antidepressant. Assessment of thyroid function might is an ideal predictor in the
treatment of GAD (Bathla, Singh, & Relan, 2016).
There are various non-pharmacological and pharmacologic recommendations for patients
diagnosed with GAD. The treatment recommendations involve psychological therapy or
pharmacotherapy, or a combination of the two. A non-pharmacologic treatment, such as
cognitive-behavioral therapy (CBT), is among the preferred first-line treatments (Bandelow,
Michaelis, & Wedekind, 2017). Other non-pharmacologic therapies include behavioral
techniques, supportive psychotherapy, and insight-oriented psychotherapy (Gautam et al., 2017).
The recommended first-line drugs include selective reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors, while benzodiazepines are not recommended for routine use.
Additional pharmacologic treatments alternatives include buspirone, tricyclic antidepressants,
moclobemide, and pregabalin. When developing a treatment plan for patients with GAD, it is
vital to consider efficacy, costs, interactions, and adverse effects (Bandelow et al., 2017).
Pharmacologic intervention should be considered in patients whose anxiety disorder
impairs activities of daily living and functioning (Lader, 2019). One of the second-line
prescribed groups of medicines for patients with anxiety is benzodiazepines. The behavioral
impact of benzodiazepines has been compared to the impact of high doses of barbiturates on the
body (Lader, 2019). Benzodiazepines are a class of prescription medication that binds to the
GABAA receptor, resulting in hypnotic, muscle-relaxing, anticonvulsant, and anxiolytic effects.
As such benzodiazepines are classified as central nervous system depressant drugs that are used
to treat acute alcohol withdrawal, depression, insomnia, excitation, aggressiveness, panic,
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phobias, anxiety and seizure among others (Lader, 2019). Traditionally, benzodiazepines are
illustrious for their sedative-hypnotic effect, inducing muscle relaxation, and causing an overall
reduction in levels of anxiety. However, it's worth noting that patients taking benzodiazepines
are highly likely to experience the “withdrawal rebound phenomenon” related to the
drug (Peppin et al., 2020). A pattern of physical dependence among patients is emerging because
of prolonged and uninhibited use of the drug. The overall inability among patients with anxiety
to successfully address the withdrawal effects is one of the first reasons why attention is turning
to the long-term effects of prescribing.
Lab experiments involving rats and dogs receiving doses of benzodiazepines have
conjointly recorded similar results, further raising their side effect profile (Balon & Starcevic,
2020). It has been tested beyond any reasonable doubt that benzodiazepines produce physical
dependencies and have a major impact on living organisms. Their reinforcing efficaciousness is
higher in individuals who ultimately develop a physical dependence to the drug. Benzodiazepine
abuse often starts with patient’s prescribed drugs that later progress to taking more than the
recommended doses before developing tolerance. Common withdrawal effects after minor
tranquillizer cessation embody perceptual distortion, insomnia, coordination problems, and
restlessness (Tyrer, 2019). These effects are particularly common among individuals blatantly
abusing the drug or those on a restively high dose of the medication. Tolerance additionally
fosters the need for higher doses for the drug to elicit an initial therapeutic effect.
Practice Gap
A consensus exists amongst professionals within the mental health care community that
there is a comprehensible need for reprioritization of psychotherapeutic treatment interventions
for addressing patient’s pathologies (Tyrer, 2019). Forward-thinking and evolving practice
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pointers would likely experience clinically exceptional benefit(s) by transitioning to a care model
that places emphasis on alternative evidence-based treatment interventions (i.e. use
of pharmacological agents with a less habit-forming profile, properly encouraging patients
regarding the perpetual need for implementing effective psychotherapeutic relaxation techniques
and devotion to sleep hygiene as well as healthy balanced life style maintenance, etc.). Clinical
literature also reiterates that benzodiazepines prescriptions, including Xanax, Ativan, Klonopin,
and Valium, should seldom supersede a month length of treatment. Therefore, the use of BZDs
in quantities and durations of time that surpass DSM-V standards should be restricted to
situations whereby patients have severe refractory anxiety-based disorders. Aggregation of data
and extrapolation of results shall transpire at psychiatric clinics or practices where patients for
this research project will be evaluated. Through utilizing anxiety treatment tool, patients with
will be able to choose a benzodiazepine-free treatment.
Benzodiazepines should be prescribed in line with the Community Behavioral Health
(2018) clinical guidelines for the prescribing and monitoring of benzodiazepines and related
medications. However, this is not always the case and there is misuse which has significant
negative effects. For instance, Lader (2019) mentioned that benzodiazepine abuse is likely to
slow the processing of thoughts and verbal abilities, which are particularly common in persons
recovering from these drugs. Benzodiazepine misuse presents two main health effects namely
withdrawal and overdose (Hirschtritt et al., 2021). In most cases, benzodiazepines are combined
with other drugs and alcohol which increases risk of overdose mainly through cardiac arrhythmia
or respiratory suppression. Further, prolonged misuse benzodiazepines increase tolerance where
patients need more doses to obtain the same effect, withdrawal symptoms and use disorder
(Lembke et al., 2018). Benzodiazepine dependence and withdrawal can start after only 4 to 6
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weeks of use and affects 20% to 30% of persons with regular use. In adults, Benzodiazepine
dependence increases chances of hip fractures falls, cognitive impairment, and drug-associated
hospital admissions (Hirschtritt et al., 2021).
The misuse of benzodiazepine has adverse effects on the patient’s family, health facility
and generally society. For instance, increased admission raises healthcare costs for the patient
and society as well (Samardzic & Svob Strac, 2016). Further, there is lost productivity which has
adverse effects on the economy (Lembke et al., 2018). The patient’s family may be forced to
take care of their kin, which has negative effects. This shows that this project which explores deescalation of benzodiazepine misuse will help in reduction of adverse health and financial effects
on the patient, their family and wider society.
The prevention of drug dependence goes a long way in managing substance abuse which
impacts a considerable cross-section of individuals on prescription medication. Dependence on
benzodiazepines is often associated with polysubstance abuse and likely to be fatal in the event if
it is not effectively managed within an appropriate timeline (Jones, 2016). Research posits the
notion that continued use of benzodiazepines is likely to serve as a gateway drug to heroin,
methadone, and alcohol use among high-dose benzodiazepine abuse (Lader, 2019). These effects
are particularly common among those individuals who are blatantly abusing the drug or those on
a restively high dose of the medication. Tolerance also fosters the need for continued higher dose
to elicit an initial therapeutic effect (loading dose). Individuals with anxiety disorder represent
an at-risk population due to their propensity to misuse prescribed benzodiazepines. The drug's
rapid onset of action and mind-altering properties further increase the chances of inducing
addiction.
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At the clinic, which will serve as the project site, prescribing of benzodiazepines often
deviates from standards of care. For patients who have been taking the medications in the long
term, opportunities to de-escalate use are not routinely offered. Even though there is a significant
number of patients prescribed benzodiazepines, providers at the project site fail to follow or
deviate from guidelines for dose de-escalation, exposing patients to possible addiction. Health
providers at the project site deviate from de-escalation guidelines due to limited time, patients'
pressure for benzodiazepines, and providers not being updated on some recent evidence-based
practice treatment (Psychiatric nurse practitioner, personal communication, June 2021). This
DNP project seeks to address this practice gap by promoting guideline utilization to promote deescalation of benzodiazepine use in adults with generalized anxiety disorder. For patients who
are naive to the medications, providers must ensure that guidelines are followed to prevent the
use or dose-escalation.
Review of Major Clinical Guidelines
There are two major clinical guidelines used in the treatment of GAD. The first guideline
is NICE. The other guidelines are APA.
NICE
The National Institute for Clinical Excellence, NICE (Clinical Guidelines for the
Management of Anxiety, 2004) published guidelines on the management of panic disorder and
GAD in Adults in Primary, Secondary and Community Care. The guideline suggests that before
any medical prescriptions are made, psychological interventions such as Cognitive Behavioral
Therapy (CBT) acts as the most effective intervention. For most patients, CBT sessions are
suggested to be conducted weekly for one to two hours. These sessions ought to be completed
within a thorough going of four months since the time of initiation. The guideline further
suggests that the medical professional considers the age, previous treatment response, if any,
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preference of the patient and the tolerability along with the risk of deliberate self-harm, observed
in patient history before making a pharmacological intervention.
Selective serotonin reuptake inhibitors (SSRIs) work with serotonin transporter and work
by increasing the levels of serotonin in the brain by blocking its reabsorption in the neurons.
They work by enhancing the functioning of the nerve cells in the brain that control emotion.
Hence, these are prescribed as first line medications and are considered relatively safer and
typically they cause lesser side effects than other medications, specifically BZD does. Serotonin–
norepinephrine reuptake inhibitors (SNRIs) are similar in function to SSRIs but they block or
delay the reuptake of serotonin and norepinephrine in the brain. Stabilization of these
neurotransmitters helps improve a person’s mood, relieve panic attacks and reduces the feeling
of anxiety.
The guideline recommends using SSRIs instead of BDZs as the preeminent choice of
medication. An SSRI should be prescribed for a period of 12 weeks and if no visible
improvement is observed, another SSRI should be prescribed. The guideline also recommends
that BZDs should only be prescribed if SSRIs are not available or unsuitable and only if there is
no improvement noticed from its use. This shows the level of caution which medical
professionals should practice before prescribing BZD. Pharmacological therapy in the form of
SSRI and self-help are long term interventions which the clinical guideline suggests having
evidence of long-term duration effects.
NICE suggests that before starting any antidepressant, the healthcare professional ought
to always contemplate the side effects of starting the medication and hence prescribe lower
dosages and slowly increase the dosage until satisfactory response from intervention is observed.
When looking at comorbid levels of anxiety, SSRIs and/or SNRIs are the first-line medicated
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interventions (Strawn, et al., 2018). The authors encourage considering age and co-morbidity in
selection of psychopharmacologic treatments. He suggests that benzodiazepine may be
prescribed as the second-line pharmacotherapies, however, SSRI, GAD, and SNRIs should be
used as first-line psychopharmacologic treatment. Concerning pediatric patients with symptoms
of GAD, SSRIs ought to be considered as the first line pharmacotherapy. The coupling if
psychotherapy with pharmacotherapy augments the antidepressant response (Strawn, et al.,
2018).
APA
The American Psychiatric Association APA (APA, 2008) practice guideline for the
treatment of patients with panic disorder suggests the use of tricyclic antidepressants (TCAs) in
case SSRIs and SNRIs fail as first-line medications. Moreover, the guideline raises several
concerns over benzodiazepine tolerance and withdrawal. The study even reports amplified risk of
accident while driving a vehicle in association with benzodiazepine use.
Both APA and NICE suggest the use of CBT alongside these medications and self-help
modeled on CBT principles. Moreover, these guidelines also suggest appropriate dosages and
prescription and since BDZs are associated with an unsatisfactory outcome in the long term, they
should not be prescribed more than 2 to 4 weeks in GAD. However, it is important to understand
that for panic disorders, benzodiazepines are not a suitable choice.
The International Psychopharmacology Algorithm Group (IPAP) released a
psychopharmacological treatment algorithm for GAD (Davidson JR, et al 2010), in which they
suggest a serial line of approach to the pharmacotherapy of GAD and recommend several
approaches past the first level of treatment. The research guideline also agrees to prescription of
SNRIs as second line pharmacotherapy intervention.

15
Literature also supports the prescription of BZDs for some patients at higher risk for
abuse. Ciraulo et al. (2000) discussed Benzodiazepine treatment in substance abuse patients and
concluded that if enough education on the risks of combining BZDs with alcohol or other
intolerable substances, and if medical professional responsibly holds transparent discussion on
diversion mechanisms and monitors for any adverse effects and misuse, then prescription of
BZDs as first-line interventions can be made under special circumstances.
El-Guebaly et al. (2010) discuss in detail the guidelines for the responsible prescription of
benzodiazepines and conclude that physiological dependence depends mostly on the dosage and
the duration of exposure. The study concluded that dependency can be reduced by intermittent
exposure to BDZs as opposed to a continued exposure. If misuse of BZDs is identified in
patients, the Canadian guidelines on benzodiazepine receptor agonist use disorder among adults
suggest a patient centric and step by step care approach to gradually decrease the dosage of
BZDs in the management of Benzodiazepine receptor agonist (BZRA) (Conn et al., 2020).
AGREE II tool was used to determine the best clinical guideline to follow. The tool was
developed by The Agree Enterprise Trust (2009). It is commonly utilized in the evaluation of the
quality and reporting of clinical practice guidelines. The tool entails 23 key items classified into
six major domains. The first domain is interested in the scope and purpose of the clinical
guideline. The second domain focuses on stakeholder involvement (inclusion of health providers,
target users, and patients). The rigor of development is the third domain, focusing on gathering
and synthesizing available evidence utilized to develop the guideline (The Agree Enterprise
Trust, 2009). Clarity of presentation, focusing on language, format, and structure of the given
domain, is the fourth domain. The fifth domain is interested in applicability in relation to barriers
and facilitators, approaches for enhancing uptake, and cost implications. The last domain focuses
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on editorial independence, ensuring that the recommendations made in the guideline are not in
any way biased because of competing interests (The Agree Enterprise Trust, 2009). Therefore,
the tool will be applicable in this DNP project as the aim is to use the guideline to promote deescalation of benzodiazepine use in adults with GAD. The tool will help appraise if the clinical
guideline followed by health providers is appropriate.
Reconciling Best-Practices
Potential Evidence-Based Solutions
Several studies have been conducted on various aspects of benzodiazepine use, misuse
and on measurers to address the health challenges posed by misuse of the drugs. For instance,
Roy-Byrne (2015) conducted a meta-analysis to investigate the best approach in the treatment of
refractory anxiety using coordinated anxiety learning and management (CALM) tool. Similarly,
Bandelow et al. (2015) explored the application of Hamilton anxiety rating scale (HAM-A) in
managing GAD among patients who had misused benzodiazepine. Similarly, Carr et al. (2019)
also conducted quality improvement project on how to implement benzodiazepine protocols
using 3-month PDSA improvement cycle.
The literature also includes clinical guidelines for the management of panic disorder and
GAD by the National Institute for Clinical Excellence (2004). The American Psychiatric
Association (2008) also published guidelines on the treatment of patients with panic disorder
suggests the use of tricyclic antidepressants. The literature supports the implementation of EBP
in de-escalation of benzodiazepine among patients with GAD (Bandelow et al., 2017; Carr et al.,
2019; Shinfuku, 2019; Liebrenz et al., 2015).
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Proposed Evidence-Based Intervention
The purpose of this DNP project is to implement a guideline compliance program that
assist in helping providers appropriately prescribe and/or de-escalate benzodiazepines use. The
aim is to address the problem of benzodiazepines misuse associated with a lack of knowledge of
the risks related to this class of medications and using the appropriate guideline to treat patients
with GAD. The proposed intervention involves educating prescribers and designing and
implementing an evidence-based reference card with guidelines for treating adult patients with
GAD.
Review of Literature
An in-depth literature review was conducted to answer the research question, “Among
adults with general anxiety disorders (P), does implementation of de-escalation benzodiazepine
program used as a guideline to safe treatment of anxiety (I), lead to reduce benzodiazepine use,
adherence to healthy lifestyle, maintance of sobriety (O) in eight weeks (T)?
A search of the nursing literature utilizing data bases was initiated. Databases searched
included PubMed, CINAHL, Web of Science, Medline, Science Direct, EBSCOhost, Google
Scholar, and ProQuest. The keywords used were benzodiazepines, de-escalation of
benzodiazepines, benzodiazepines abuse, benzodiazepines misuse, clinical guidelines for
benzodiazepines prescription and monitoring. Over 42 articles retrieved and after reviewing
reports, the articles that directly discussed de-escalation of benzodiazepine use in outpatient and
inpatient settings were included. All evidence was appraised using the Melnyk -Fineout
Overhold Rapid Appraisal Forms. In three articles randomized control trials was used, 5 articles
non-experimental design was used while in two articles systematic review of the literature was
conducted. Different data was used to examine regional variation in trends in the relationship
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between anti-anxiety medications (SSRI), different treatments (cognitive-behavioral therapy and
combination) and BZDs. To facilitate generalizability, only participants with DSM-V GAD were
selected. All studies used the instruments for measurement of anxiety.
Relevant Studies
Adult patients with anxiety disorder often abuse prescribed medications for their
respective condition. A meta-analysis by Bandelow et al. (2017) examined pre-post effect in
relation to changes in size prior and after commencing treatment with medications and
psychotherapies. A total of 35,000 patients aged between 7 years and 65 years were included as
an ideal sample population for the psychotherapy studies. The result would later indicate that
individuals within this group exhibited less damaging effect within an outpatient setting that has
been taking BZDs for a short time. The Hamilton Anxiety Rating Scale (HAM-A) was also
utilized as an ideal diagnostic measure and analysis based on frequency and relative risk. The
findings recorded indicated a significant decrease in anxiety levels after the implementation of a
drug treatment regimen and CBT. In relation to the synthesis of this scholarly work, the evidence
was robust and supported the treatment of GAD. The authors present the evidence that strategies
other than BZDs are being used to treat anxiety and they substantially decrease levels of anxiety
among adult patients. It would, therefore, go a long way in contributing to the application of
tools and large data in the diagnosis and rating of patients with anxiety and on benzodiazepines
as depicted in Table 2 (Appendix A).
Using meta-analysis methodology, Roy-Byrne (2015) sought to determine the best
approach in the treatment of refractory anxiety over 12 months, 69 participants were receiving a
different treatment for anxiety. The CALM tool was ideal for this study, especially in relation to
identifying the most appropriate treatment options for individuals with anxiety. Similarly, to the
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other studies, negative results of BZDs including high risk for dependence are explained along
with a need to use strategies for improved assessment to determine best practice. The analysis
was based on the actual frequency of using benzodiazepines, its relative risk, and other available
options. The strength of the evidence provided was on its focus on multiple treatment options
and the amalgamation of CBT as depicted in Table 2 (Appendix A). Authors present evidence
that the clinician should proceed by exploring combination treatment with multiple modalities
(this has usually been tried already) and then either multiple novel medications, more aggressive,
longer-duration CBT, or a switch to another psychotherapeutic modality such as IPT or
psychodynamic psychotherapy as depicted in Table 1 (Appendix A).
In a meta-analysis and a systematic review, Bandelow et al. (2015) compared the relative
efficacy of pharmacological intervention as opposed to a combined treatment for GAD, panic
disorder (PD). A total of 37,333 participants took part in the study which also included
randomized trials with adults receiving pharmacological treatment for GAD. Similarly, the
HAM-A was applied to this case of data analysis conducted based on frequency and relative risk.
The preliminary findings recorded in this study indicated a lower level of anxiety after the
implementation of a treatment plan with a selective serotonin reuptake inhibitor (SSRI). The
study’s transparent design, analytic approach based on the HAM-A scale and the presence of a
predefined question, later answered appropriately, were some of the major strengths noted during
the initial appraisal as depicted in Table 2 (Appendix A). However, the researchers’ overreliance
on a single viewer framework in the evaluation of published literature and the presence of mixed
treatment meta-analyses were among some of the major weaknesses noted. This was further
compounded by insufficient data when conducting respective statistical analyses. The authors
provide evidence that selective serotonin reuptake inhibitors (SSRIs) are the most effective
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treatment option for adults with anxiety and can be used as first line treatment. Therefore, steps
to de-escalate BZDs use are taken by prescribing SSRIs (Bandelow et al., 2015).
A meta-analysis by Platt (2016) sought to ascertain the impact of using BZDs versus
alternative treatment options. A total of 12 studies were appraised, in addition to the participation
of 1338 adult patients with anxiety over a six-month period. The GAD, PDSS, and SPIN were
ideal tools for this study as depicted in Table 2 (Appendix A). The analysis was based on the
actual frequency of using benzodiazepines. The findings indicated that natural non-chemical
anxiolytic treatments are available and can be safely recommended for patients. The strength of
this study was in its use of empirical data while its weakness which went a long way in painting
an elaborate picture of benzodiazepine addiction as a major public health issue. Similarly, to the
other studies, contribution is to support that overuse of benzodiazepine drugs to treat anxiety,
mood, and sleep disorders are a growing problem in clinical practice (Platt, 2016).
Utilizing a randomized control trial, Shinfuku (2019) investigated the short-and longterm effects of benzodiazepines. A total of 1228 participants took part in the study over a 13week period. IV1 Tx, no Tx recorded for IV2, other Tx for IV3, and the level of anxiety for
DV1. Similarly, to other studies, HAM-A tool was implemented to gauge the efficacy of
treatment option and an accompanying analysis based on relative risk and frequency of use.
After the first 8 weeks, it was discovered that no significant differences existed between
prescribing benzodiazepines and antidepressants. The study was well designed, with accurate
findings which supported the proposition. However, the limited number of studies used meant
that further investigation on the role and safety of benzodiazepines. This study supports that
long-term BZDs use is not endorsed in the treatment for anxiety disorder but is prevalent in the
real-worlds clinical settings and presents gaps in evidence-based practice. It also presents
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evidence that alternative interventions such as CBT, non-BZD medications have better outcomes
in lowering anxiety level and de-escalating BZDs use as depicted in Table 2 (Appendix A).
Using quasi-experiment design, Carr et al. (2019) conducted quality improvement project
that encouraged patients to commit to deprescribing BZD protocols and improve upon current
benzodiazepine deprescribing archetypes within 3-month PDSA improvement cycle. Strength of
the study are high specificity, procured optimal outcomes, relevant information regarding
implementation of deprescribing protocols for adults (65+ years of age). Small sample size and
data is limited to adults over 65 years of age. Information can be used to design and conduct
future studies with larger sample size and population. Data alludes to potentially promising
deprescribing protocols and provides insight into commonly encountered complications.
Information can be used to design and conduct future studies with larger sample size and
population. Data alludes to potentially promising deprescribing protocols and provides insight
into commonly encountered complications. Authors present evidence that medication review,
patient education, brief counseling helped empower patients and deprescribing BZDs was
effective strategy to de-escalate BZDs use as depicted in Table 1 (Appendix A).
Given the significance of drug dependence, Liebrenz et al. (2015) conducted a qualitative
study with 41 adults that were meeting criteria for BZD-dependence according to the 10th
revision of ICD-10. Highlighting patients’ self-reporting beliefs and perceptions on factors
contributing to their initial BZD use for mental disorders, as well as treatment preferences and
how they obtained BZDs. Primarily conducted to document patients’ thoughts and perceptions
about BZD use; assess trends and data to note applicability and utility value to development of
refined comprehensive treatment planning. Strength of this study aggregate unadulterated
subjective data reports from patients with thoughtful reflections on their reasons of BZD use.
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Weakness was the limit in its ability to provide high-quality data with robust utility value; there
is an inability to make evidence-based inferences after completion of the study. Participation was
voluntary; therefore, there is an immediate inherent bias. Subjective patient reports provide
assessment data pertinent to constructing future hypotheses, research studies, and treatment
plans.
It is acute need of the time to identify BZD misuse risk factors prior to prescribing.
Health care professionals are required to use innocuous alternatives, and to make fitting
interventions to decrease the ongoing abuse. Since BZDs since have a place in therapy
interventions of GAD, education of patients on the risks is tasked with a prescriber. Treatment
plans and monitoring measures for abuse of substance need to be carefully implemented in the
future with the aim of reducing inappropriate prescription rather than targeting all prescriptions.
This will maintain accessibility to applicable patients with appropriate medical use symptoms. In
this case, health care professionals must also keep themselves abreast with latest developments,
abuse patterns and trends to divert abuse of prescribed substances.
Synthesis of Literature
Although the reviewed experimental studies (RCTs and quasi-experimental) had a wide
range of similarities in their proposed EBP intervention, they still possessed marked differences
which were unique to each study. Bandelow et al. (2017) and Shinfuku (2019) randomly selected
large sample sizes ensuring generalization of their findings while Liebrenz et al. (2015) and Carr
et al. (2019) had smaller sample sizes. Participants in all the studies were classified as adults
between the ages of 18 to 65-70 years except for one study that focused on pregnant women. The
inclusion criteria of all the studies stressed on and underlying diagnoses. Although an underlying
inclusion criterion for participants in all the studies was receiving antianxiety medication and did
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not specify other possible conditions contributing to anxiety. All studies used for this literature
review adopted the same EBP intervention which stressed on the effect of psychoeducation on
mediation choices among participant to decrease benzodiazepine use. Through psychoeducation
on lifestyle changes among participants to decrease benzodiazepine use, all studies reported that
participants experience less anxiety, higher productivity, and overall feeling healthy after they
started exercising, meditating, walking, and started psychotherapy. Participants in the RCT study
by Shinfuku (2019) were requested to frequent toxicology test to rule out BZDs use. Increased
knowledge on available treatment options and healthy lifestyle choices was however noted in all
participants of the various studies. A total of 11 guidelines were reviewed with a wide range of
similarities in their proposed evidence-based projects (EBP) intervention, the studies still
contained marked differences which were unique to each study. Some studies (Schmitz 2016) do
not associate the role of gender in distinguishing abuse of BZDs. Whereas APA guideline
suggests that females are not only more likely to abuse when they have a history of substance
abuse but rather females are also susceptible to boss density loss from the use of SSRIs. All
guidelines recognize the need for second- and third-line prescriptions if the first interventions
don’t show promising results.
Participants in all the studies were classified as adults between the ages of 18 to 65-70
years except for the study of (Rubinchik, et al. 2005) which sampled adults before the age of 49
since the focus of the study were female patients of GAD who were also pregnant. This study
also examined children of up to 18 months of age who were exposed to BZDs interventions.
The addition criteria of all the studies stressed on and underlying diagnoses. Although an
underlying addition criterion for participants in all the studies was receiving antianxiety
medication and did not specify other possible conditions contributing to anxiety. All studies used
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for this literature review embraced the same EBP intervention which stressed on the effect of
psychoeducation on mediation choices among participant to decrease benzodiazepine use.
Through psychoeducation on lifestyle changes among participants to decrease benzodiazepine
use, all studies reported that participants experience less anxiety, higher productivity, and overall
feeling healthy after they started exercising, meditating, walking, and started psychotherapy.
Guiding Theory
The theoretical framework that would assist with implementation of this evidence-based
project (EBP) is Kurt Lewin’s Change Theory. This theory was first introduced in the 1940s. It
provides a ground for effective implementation of change by a person or an entire group of
people (Curtis et al., 2016). For a patient with a new or currently existing diagnosis of anxiety to
adapt to changes in medications and lifestyle through psychoeducation, going through a
transformational change would need to occur. This change process goes beyond the superficial
alterations which are easily noticeable to address the mental and emotional need to attain
wellbeing.
Lewin’s change theory is based on three basic core concepts. First one is ‘driving force’,
the second is ‘restraining force’ and equilibrium being the third, which are simply referred as
unfreeze, change, and refreeze (Lewin, 1999). In this model work is divided into three
categories. Each category represents a step. Step one is Unfreezing. The subjects are made to
unlearn their old habits. Different methods of perspective changing, and unlearning can be
applied according to the subject. In the change phase new habits are introduced to the subject. In
this stage compatibility of subject with the new method is also recorded. If this change process is
successful, we enter the third and final stage that is refreeze. In this stage we try to make this
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newly introduced habit a permanent habit. This will require periodic follow ups and deadline
setting.
Lewin stated that while driving force tends to move in the directed direction, restraining
forces which are also present, act as a barrier in the path of our new change process. The
interaction of these forces usually causes imbalance however when restraining forces become
equal to driving forces, equilibrium is reached and as result no change takes place. Recognizing
the restraining forces timely, and successfully decreasing them is essential to achieve the desired
effect of the newly introduced change. Prescriber should reinforce a patient’s desire to obtain a
healthy mind that will be used as a driving force for treatment while discouraging misuse of
benzodiazepines which acts as a restraining force. Using the principles of Lewin’s Change
theory, prescribers should provide the patients with tools and knowledge to learn and apply this
knowledge to get healthier lifestyle. This helps patients to be less dependent on medication while
managing their anxiety and staying benzodiazepine free.
In 1999 Lewin and Gold explained that it is necessity for any social change to work that
the patients should be able to reference whenever needed, by ensuring reinforcements and follow
ups. Properly and systematically educating patients about danger of prescribed benzodiazepines
medications and alternative options to treat anxiety through psychoeducation can potentially
bring people towards healthier lifestyle and navigate towards protecting each other and
enhancing overall patient outcomes with decreasing benzodiazepine crisis.
Application to the DNP Project
The de-escalation benzodiazepine program patterned through Kurt Lewin’s Change
theory contributes to the stages that the patient with anxiety was going through during the
project. Lewin’s complex processes were explained in three major stages of change. These stages
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were referred to as unfreezing, moving, and refreezing; that an individual went through to
achieve lasting change (see Appendix B).
In the unfreezing stage of change, the prescriber helped the patient, who may be misusing
benzodiazepine, to understand the value and need for change, through detailed education (Lewin,
1999). The first stage, unfreezing, tends to decrease hostility to change from an inadequately
educated patient about the need for change. This is a significant phase in the change process as it
predicts the patient’s reactions towards the change and points out if the process needs to be
revised. During this phase, patients were educated on the negative long-term benzodiazepine use
and other alternative strategies and medication regimens available should be shown to them. The
potential risks of benzodiazepines were discussed thoroughly with patients because it is very
necessary that the patient understands the process and importance of this project. To make sure
that the patient can understand the rationale behind the initiation of this change process, effective
communication crucial in this stage. The prescriber assessed the patient’s currently used
medications, his habits and any factors contributing to their anxiety.
After educating about the need for change and benzodiazepine misuse during the
unfreezing stage, the second stage, the moving stage, focused on developing a favorable
environment for change to occur (Curtis et al., 2016). In this stage, the prescriber introduced or
reinforced healthier options to treat anxiety which guided patients to meditation, exercise,
therapy, and prescribed alternative anti-anxiety medicines.
In the final stage of change theory, refreezing, stakeholders decided whether the change
was successful or not while discussing challenges encountered or still facing, areas requiring
improvement as well as planning for the way to move forward (Curtis et al., 2016). After making
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sure that the new change is working for the patient, the prescriber tried to make this change a
permanent habit.
Organizational Description
Setting
The project implementation occurred in an outpatient behavioral health clinic in Las
Vegas, Nevada, in the summer of 2021. The clinic provides care to over 6,000 clients yearly with
diverse mental illnesses including GAD. The team at the mental health clinic included
psychiatrists, doctoral and masters prepared psychiatric nurse practitioners, medical assistants, an
office manager, laboratory service personnel, information technology (IT) personnel as well as
accounting/billing department. The clinic serves clients that over the age of 18 years to geriatric
population. The common diagnoses managed at the clinic include bipolar disorder, depression,
schizophrenia, substance abuse, posttraumatic stress disorder, attention deficit hyperactive
disorder and anxiety disorder.

All patients receiving treatment at the clinic had some form of private, state, or federalfunded health insurance while others are private pay clients. Some of the clients are homeless
residing at shelters who have health insurance coverage. The clinic is conveniently located on the
public transportation route with primary care outpatient clinics as well as other healthcare
facilities within proximity. The setting was selected for implementation of the project because of
patients’ subjective reports and objective assessment of benzodiazepine induced side effects
including dependence as well as willingness to change to alternative strategies to treat anxiety.

Stakeholders
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The Calm Clinic in Las Vegas, Nevada is part of a larger of franchise of health facilities.
In this regard, organization stakeholders are the clinic management lead by the board and the
chief executive officer. The management was expected to allow for the project to take place at
the clinic and use of the resources. The organization management was also expected to
implement the EBP findings if they meet outlined thresholds.
The interprofessional team at the practice site included psychiatrists, doctoral prepared
nurse practitioners, medical assistants, an office manager, information technology (IT) personnel
as well as accounting/billing department. Team members participated in this project according to
their scope of practice and job description. The psychiatrists and other nurse practitioners
referred patients, who were prescribed BZDs medications, to the Principal Investigator (PI) who
was responsible for providing psychoeducation. Scheduling of participants for this project was
the responsibility of the medical assistants. The preceptor for this project served as a resource for
the PI while Information Technology (IT) personnel assisted in retrieving a list of patients with
anxiety that are prescribed benzodiazepines from the electronic medical records (EMR) in the
clinic. Project participants constituted an important group of this project’s stakeholders whose
understanding and implementation of the psychoeducational intervention were evaluated at the
end of the entire project.
The major stakeholders within the ambulatory care setting who benefited from deescalating benzodiazepine use program involved patients with anxiety, their families, healthcare
providers involved in care, interdisciplinary healthcare team, insurance companies, and
pharmaceutical companies. Some of the major drawbacks to integrating de-escalating
benzodiazepine use within outpatient psychiatric care settings stem from being unaware of
existing drug use, obtaining benzodiazepine from other sources, and receiving care from other
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clinics with mental health services (Bersani et al., 2017). De-escalating benzodiazepine use in
general has been supported by many professional groups.
DNP-prepared nurses or Advance Practice Nurses (APNs) with a specialization in
psychiatry are well trained and well vexed in identifying, diagnosing, treating, and managing
mental health disorders including GAD within the outpatient care setting. Although there were
different avenues to integrate mental health services, the most beneficial approach is
coordination of care (Olfson, 2016). In this way, patients with GAD who need a proper
assessment using evidence-based practice tools, are directed to a clinic where the continuation of
care can be provided (Olfson, 2016). Some of the disadvantages to this method of care delivery
may be lack of reliable transportation to appointments, high copays, and conflict in schedule.
Olfson (2016) describes a model of care where providers can receive specialized training in
mental health disorders such as anxiety and continuation of holistic care, so continuation of care
is smooth. In this business plan, the project is an advanced step further and instead of training
Primary Care Providers (PCPs), DNP-prepared Psychiatric Mental Health Nurse Practitioners
offer mental health services with de-escalation of benzodiazepine use and their follow up
appointment. This decreases continuation of the same medication regimen that involves
benzodiazepines, decreases risk for misuse, costs of care, and improve patients’ outcomes.
When de-escalation of benzodiazepine use programs are integrated into the treatment plan of all
the patients with diagnosis of GAD and BZDs use, there is a multidisciplinary team involved and
that decreases the risk for polypharmacy as well as provision of care to ensure that mental care
needs are met without gaps.
Organization Assessment
Regarding informatics, the clinic has integrated various technologies into its operations.
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For instance, there are electronic medical records for storing patient records and the use of
computerized physician order entry. In line with the project purpose the clinic uses electronic
prescription which will be used to retrieved records to evaluate the project progress.
At the clinic there is a holistic approach to delivering services to patients. The clinic
leadership ensures that there are adequate human and fiscal resources to deliver feasible services
in line with federal requirements and existing clinical guidelines. Also, there is coordination and
collaboration between health care practitioners involved in patient care.
Strengths. The clinic has an organization where it is dedicated to evaluating existing
ways of delivering services and improving them where there is need. Also, the clinic leadership
has consistently supported and encouraged implementation of EBP which they are convinced
about positive effects on the organization. The clinic has qualified and experienced team of
psychiatrists who implemented the project.
Weaknesses. Whereas the organization is devoted to improving of services and
implementing of EBP, only a few have been conducted at the site and their findings
implemented. The organization has set a high threshold for approving EBP projects at the site
and adopting their findings.
Opportunities. Providing an intervention to reduce the misuse of BZDs leads to an
improvement in patient outcomes and have positive effects on the organization. The clinic
attends to patients who have been diagnosed with GAD hence there is an opportunity to deescalate the use of BZDs.
Threats. One threat was that the project was affected by COVID-19. There
were regulations that limit physical contact and there was a chance of a ban on
movement. This could lead to project discontinuation or postponement until such a
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time it is feasible to implement as conceptualized.
Congruence
Risks associated with using benzodiazepines raise concern among patients and
healthcare providers. Internal evidence such as patient’s clinical status/circumstances, patient’s
preferences, and outcomes of quality improvement projects were considered during clinical
decision making (Bersani et al., 2017). For this project, in addition to patients’ subjective reports
of benzodiazepine dependence and exacerbation of symptoms of anxiety, underlying disease
processes related to prescribed benzodiazepines, patient’s current underlying factors, lifestyle,
stressors, dietary habits, medical conditions as well as physical activity level were analyzed prior
to delivery of psychoeducational intervention and decreasing or discontinuing benzodiazepines.
This internally generated data was compared with national and global statistics of the problem of
benzodiazepine use crisis, fetal risks of its misuse and its impact on society.
The project took place at the Calm Clinic that is a Limited Liability Company (LLC)
where patients with mental health needs received services at the same location as their outpatient
mental health clinic-Anywhere Clinic. Alterations were made to the initial introduction of the
program to the potential clients who are in the mental health clinic. The practice is operated by
board-certified Psychiatrist Mental Health Nurse Practitioner and includes services offered by a
board-certified DNP-prepared psychiatric nurse practitioner. Calm Clinic as a mental health
practice was originally formed by Psychiatrist, Dr. Sam Zand in 2017. The main mission of the
practice is to help patients to maintain mental health in a compassionate and professional
environment. Their philosophy is to allow patients having a healthy and enjoyable life with an
organizational goal for the team to provide a high quality, patient-centric, and safe care for the
patient who suffer from anxiety and risking benzodiazepine dependence. Additionally,

32
decreasing benzodiazepine prescribing and therefore use by implementing de-escalating
benzodiazepine program and education (Johnson & Garvin, 2017).
Statement of Mutual Agreement
The clinic’s management and practitioners working at the facility have agreed to
collaborate with the DNP student towards the implementation of this project. The management
has permitted the student to implement the project at the facility towards improving
benzodiazepine prescription practices among the practitioners at the clinic.
Methodology
Aims & Objectives
The purpose of the project was to implement a guideline compliance program that assists
in helping providers appropriately prescribe and/or de-escalate benzodiazepine use. Through this
program, prescribers were challenged to better utilize evidence-based practice guidelines when
providing care for adults with GAD via a reminder card. This helped to reinforce best practice
and ultimately reduce long-term risks to patients. Specific goals were to adhere to guidelines, deescalate benzodiazepine use (when appropriate), and promote sobriety (T) over an eight-week
time frame.
Objectives:

I.

Provide education to prescribers to reinforce evidence-based guidelines in treatment of
GAD and reinforce this teaching via a reminder card summarizing the guidelines for
GAD on one page.

II.

Evaluated Outcomes:
a. Compliance Outcome 1: Ensure that 100% of patients were offered a nonpharmacologic adjunctive therapy at each visit

33
b. Compliance Outcome 2: Ensure that 100% of patients receiving appropriate
medications either:
i. If Benzodiazepine Dependent: offered opportunity to de-escalate at each
visit. The goal was to reduce the benzodiazepine prescriptions by 50% or
more.
ii. If Benzodiazepine Naive: offered alternative or appropriate use of
benzodiazepine per the GAD guidelines.
c. Health Outcome (Anxiety): The anxiety level of all the patients were monitored.
The goal was to have reduction of anxiety from baseline, though the response may
be very individualized.
d. Process Outcome 1: At least 75% of the prescribers at the Calm Clinic reported
use of the reminder card while treating their patients with GAD.
e. Process Outcome 2: 100% of providers completed the program evaluation for the
purpose of feedback and improvement.

Implementation Framework
The Plan-Do-Study-Act (PDSA) cycle served as the guiding framework to evaluate
current guidelines used in screening, diagnosing, and treating adults with GAD (see Figure 1).
The PDSA cycle is an iterative, four stage problem solving model used for improving a process
or carrying out a change (Coury et al., 2017). It is often used in quality improvement projects,
where the aim is to improve the quality of care through collaborative changes in practice.
Step 1: Plan
During Step 1, the DNP student recruited a team comprised of relevant stakeholders
required to implement the change – 6 clinicians and administrative staff. Then, an initial meeting
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to discuss the current treatments for patients with GAD, educate on benzodiazepines, and
introduce a reminder card with the preferred guideline. The primary investigator discussed the
importance and benefits of using GAD-7 to measure anxiety levels objectively, SSRI as first-line
treatment v benzodiazepine, CBT as adjunctive therapy, and importance of offering the
opportunity to de-escalate current benzodiazepine use. All relevant partners were notified of the
study prior to the start date.
Step 2: Do
Step 2 involves implementing the reminder card. Three providers recruited patients to the
project who are being treated for Generalized Anxiety Disorder. The providers utilized evidencebased guidelines and the card to treat the patients. Over a eight-week period, data was collected
to determine their level of success with project outcomes (previously listed). Patients were
assigned a random number for de-identification and chart reviews were completed
retrospectively to evaluate project outcomes: 1) offered a non-pharmacologic adjunctive therapy
at each visit; 2) offered appropriate medication therapy (naive v dependent); 3) objective
evaluation of anxiety via GAD 7; and 4) overall number of benzodiazepine prescriptions used.
Step 3: Study
During Step 3, the project leader hosted discussion to gather feedback from the providers
who used a quick reference card while treating adult patients with GAD, focusing on barriers and
facilitators to implementation. To understand if the education and card resulted in an
improvement the number of BZDs prescriptions, therefore, de-escalation of benzodiazepine use
were assessed. In tandem, discussions about experience of using the card informed about needed
improvements in using the guidelines.
Step 4: Act
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Step 4 involved a final assessment of the process and thoughts on how to move ahead.
The Act stage in this process for improvement was two-fold. Using the information and
revelations assessed in the study phase, the team updated and altered the plan for change to build
on change facilitators and address barriers to implementation. This step also involved
documentation describing the outcomes of this process, including publication of results, so that
others can evaluate the evidence generated here and consider changes in clinical practice. The
second part of this phase was to reflect and create documentation that describes the outcome of
this process so that others can see the outcome of this study and make their own plans for
change.
Population and Setting
The population targeted in this change project was prescribers who are physician
assistants and nurse practitioners treating adult patients diagnosed with GAD. This study
occurred at the Calm Clinic in Las Vegas, Nevada. The clinic was responsible for providing
outpatient mental healthcare for adults. Using the evidence-based practice guidelines to treat
patients diagnosed with GAD while de-escalating benzodiazepine prescribing was a critical goal
for the clinic.
Recruitment Method

Following IRB approval of the project, the providers utilized the card. After 8 weeks, the
patient charts were reviewed. The charts were selected if the patient was 18 years old and older,
diagnosed with GAD, and being treated at the Calm Clinic. Patients were English-speaking
(Appendix H). The goal was to recruit 30 patients minimum, 50 maximum per provider (6) over
a period of 8 weeks.
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IRB Submission Process & Ethical Considerations

A review application for Internal Review Board (IRB) approval was obtained from
Eastern Kentucky University (EKU) before the beginning of this project. After receiving
approval from EKU’s IRB.

Though the patients were treated for a mental illness, the goal of this project was to help
providers comply to standards of care. Therefore, there was no increased risk to the patient. It is
important to note also, that ultimately the decision to prescribe medication was made between
the provider and with the input of the patient. Especially in the case of de-escalating use of
benzodiazepine use in patients already using the medication, the goal was to offer the
opportunity to de-escalate. Patients may choose their own path/therapy with the supervision of
the individual medical provider. The reminder card was designed to merely “remind” the
provider of best practice. The patient chart review was purely retrospective.

Instruments
Demographic & Pre-Intervention Form
The providers involved in the project were asked to complete a simple demographic form
that describes their age, medical training, and experiences with benzodiazepine prescribing. The
goal was to describe the population and document their input and perspective (Appendix C).
Chart Review
Patient information were organized by provider. Under each provider, the patients were
assigned a random number for chart review and the master list linking the provider and patient
maintained at the Calm Clinic by the primary investigator in the secure electronic health record.
Each chart was reviewed to ensure:
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•

Offered of a non-pharmacology therapy at each visit for GAD

•

Offered of appropriate medication therapy and/or opportunity to de-escalate

•

Assessed anxiety using GAD-7

•

Number of overall benzodiazepine prescriptions per provider pre and post
intervention

GAD-7 Scale
To measure the anxiety level of the patients, pre-intervention and post-intervention, as
well as during the 8-week implementation time, GAD scale-7 or GAD-7 scale was used (see
Appendix D). This tool is a self-reported questionnaire that screens the severity of the anxiety of
the patient. There are seven items or questions in the GAD-7 scale. The GAD-7 items include:
1) nervousness; 2) inability to stop worrying; 3) excessive worry; 4) restlessness; 5) difficulty in
relaxing; 6) easy irritation; and 7 fear of something awful happening (see Appendix D).
Assessment is indicated by the total score, which is made up by adding together the scores for
the scale of all seven items. It measures the severity of different signs of GAD with each having
some assigned points. The questions included are regarding excessive worry, easy irritation, fear
of something awful happening, difficulty in relaxing, inability to stop worrying, nervousness, and
restlessness. Each of these measures has a score rating of 10, and together they make total of 70
points. The specificity value is 0.82 and sensitivity value is 0.89 to identify as GAD diagnosis.
The GAD-7 scale was developed in 1990s, and currently it is the most used tools to assess the
anxiety level for GAD (Pascal et al., 2017).
Process Evaluation
During this project, a data collection form was provided to participants on the first and
last day of the follow up appointments. The form collected information on anxiety level and
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number of benzodiazepine prescriptions before and after starting the quick reference card use.
Participants also completed a weekly log, during the 8-week of project, which tracked their
BZDs scripts and patients GAD scores (see Appendix G).
Data Analysis, Security, and Storage
Only de-identified patient data was extracted during chart review. The chart review
spreadsheet was kept locked in the office of the primary investigator at the Calm Clinic. After
three years it will be destroyed as per EKU IRB policy.
Data was analyzed in chart review using measures of central tendency – mean, median,
and mode. A paired sample, t-test was used to compare GAD-7 scores pre and post intervention
for each domain. Cohen D efficient was used to determine overall effect. The process evaluation
form was reviewed by two reviewers and coded for themes.
Timeline of Project Phases
Recruitment period of participants occurred approximately 7 days prior to the beginning
of this project (see Appendix J). The eight-week de-escalating benzodiazepine project was
conducted in the clinic within an eight-week timeframe while still preserving the fundamental
principles of the project. Participants reported results from appointments weekly, for eightweek. The participants were established prescribers that work at the Calm Clinic. During the
first meeting with the project leader, participants provided general information about the project
and all guidelines on quick reference card. The Medical Assistant (MA) assisted with data of the
patients which took about 15 to 20 minutes and was completed before the first and the last
appointment.
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Anticipated Implementation Barriers
The project sample size represented might be a small fraction of the target patient
population which could have benefited from this project. The eight-week timeframe for project
implementation and evaluation might not be adequate to assess the long-term use of quick
reference cards by providers. Participants’ personal assessment of using quick reference cards as
well as alternative strategies to manage anxiety might pose a limitation to the project due to
possible discrepancies in reporting. The community impact of the COVID 19 pandemic caused
anxiety among patients might be leading to lower involvement in the project at the end due to
underlying medical conditions which affected project sample size.
Results
The IRB approved the project on 10/08/2021. Recruitment of providers began
10/08/2021. A total of 6 (N=6) participants who were Mental Health Nurse Practitioners
completed the pre and post-test assessment. There were 3 females and 3 male participants within
the age range of 30 to 50 years of age: with a mean age of 36.
Compliance Outcomes
To assess compliance outcomes patient chart audits were completed anonymously and
with permission of patients’ provider. In total of 69 patients’ charts were reviewed. The charts
were audited to determine if outcomes were met.
Outcome 1: Charts were reviewed (N=69) and all the patients were offered CBT,
exercise, meditation during the first appointment as a baseline and moving forward, continuing
to monitor for 8 weeks. The goal to offer 100% of patients a non-pharmacologic adjunctive
therapy at each visit was fully met.
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Outcome 2: Benzodiazepine Prescriptions. The goal of this outcome was to ensure that
100% of patients received appropriate medications. Over the 8-week period, 16 benzodiazepine
prescriptions were written for the selected sample of patients (N=69). Of these prescriptions,
n=16 were given to the patients who were already using benzodiazepines, n=2 were given to the
patients who were benzo naive. The average number of benzodiazepine prescriptions written to a
group of 69 patients before introducing the quick reference card was 18 that included 4
prescriptions for benzo naïve patients and 14 for the patients who have already used the
benzodiazepines. This indicates decrease in benzodiazepine prescriptions by 11% over the 8week period. The goal to reduce prescriptions by 50% was not met, however, the PI intends to
monitor the data.
The documentation in the chart indicated that 100% of these patients (N=69) were
offered the opportunity to de-escalate benzodiazepine use by decreasing doses, alternative
medications, psychotherapy or were prescribed medications according to guidelines, therefore,
the goal of providing 100% of patients appropriate medications was met. This outcome goal was
fully met.

Health Outcome: The anxiety level of all the patients (N=69) were monitored. The goal
was to have overall reduction of anxiety in a group after reinforcing guideline adherence. The
overall average on GAD-7 pre-intervention was 15.83 among all participants. The overall
overage post-intervention was 10.90 among all participants. When analyzed, a paired sample ttest demonstrates a p -value of <0.001 which indicates that statistical significance was met. The
finding was clinically significant because demonstrated decrease in GAD-7 scores when
guidelines were followed by prescribers. The Cohen’s d of (68) which indicated a large effect.
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Process Outcomes

Outcome 1: Use of Guidelines. At least 75% of the prescribers reported use of the
reminder card while treating their patients with GAD. Collectively, 5 out of 6 participants
(83.33%) reported a consistent use of a quick reference card, 1 participant (16.67%) reported not
being consistent with using the card.

Outcome 2: Program evaluation. A post intervention evaluation form was completed
by all six participants on the last day of the group sessions. All participants (N=6; 100%)
reported the sessions provided an overview of the EBP guidelines to treat GAD and explained
the risk of benzodiazepines use. All the participants (N=6; 100%) reported the sessions provided
tips on alternatives treatments for patients with GAD and ways on how to decrease number of
BZDs prescriptions. All participants (N=6; 100%) reported the group sessions resulted in
substantial reduced number of BZDs prescriptions through alternative medications and therapies.

Discussion
The findings indicated that utilizing EBP guidelines in treatments of patients with GAD
decrease overall scores on GAD-7 and reduce number of BZDs prescriptions. Approximately
two-thirds of patients showed improvement and recovery from their symptoms of anxiety, and
three-quarters showed reliable improvement on symptoms of anxiety. Several RCTs (Bandelow
et al., 2017; Shinfuku, 2019; Liebrenz et al., 2015; Carr et al., 2019) and qualitative study
(Liebrenz et al., 2015) support the need to utilize guidelines to de-escalate use of
benzodiazepines in treating patients with GAD through psychoeducation enforcing using
alternative treatments and therapy. The literature reviewed in this project highlighted the positive
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impact psychoeducation which emphasized first line treatments and guidelines for GAD,
decreased use of benzodiazepines by choosing alternative anti-anxiety medications and
treatments (Bersani et al., 2017). The findings from this project are consistent with the literature.
Participants reported improvement with their anxiety level as they were engaged in
therapy and non-BZDs over the eight-week period of this project. The finding from the project
was clinically significant because demonstrated decrease in GAD-7 scores when guidelines were
followed by prescribers. Results of the paired t-test, presented in Table 3, compared the pre and
post GAD-7 scores as well as a paired sample t-test for the overall GAD-7. There was significant
increase in pre-test score for GAD-7 (M = 15.83, SD = ± 2.74) compared to post-test score for
GAD-7 (M = 10.90, SD = ± 4.81) (Table 3).
Although, the goal to reduce prescriptions by 50 % was not met, 100 % of the patients
were offered the opportunity to de-escalate benzodiazepine use by decreasing doses, alternative
medications, psychotherapy. Based on the outcome of this project, utilizing EBP guidelines to
de-escalate BZDs use with an emphasis on alternative medications and therapy can increase
awareness and reduce benzodiazepine use. It also encourages behavioral changes on ways to
manage care for patients with GAD and being prescribed BZDs.
Limitations
The project sample size (n=69) represented might be a small fraction of the target patient
population which could have benefited from this project. The eight-week timeframe for project
implementation and evaluation might not be adequate to assess the long-term use of quick
reference cards by providers. Participants’ personal assessment of using quick reference cards as
well as alternative strategies to manage anxiety might pose a limitation to the project due to
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possible discrepancies in reporting. The community impact of the COVID 19 pandemic caused
increased anxiety among patients but might be leading to lower involvement in the project at the
end due to underlying medical conditions which affected project sample size.
Implications
Clinical Practice
The EBP project focused on educating participants on EBP guidelines that will reduce
prescribing BZDs through psychoeducation, using alternative anti-anxiety medications, and
encouraging therapy. The intervention was successful in improving patient outcomes as
evidenced by the post-intervention data and is aligned with the overwhelming support for
psychoeducational intervention in already existing literature (Bandelow et al., 2017; Carr et al.,
2019; Liebrenz et al., 2015; Shinfuku, 2019). This eight-week project although brief in time
frame, suggested benefits for a longer duration of a similar project. The DNP-prepared nurse
could thus play a leading role in identifying, implementing, and sustaining facility wide changes
which would improve the overall wellbeing among the patients diagnosed with GAD.
Policy
At the local, state, and national levels, advocacy for legislations and programs which
would improve health literacy through providers’ education especially among mental health
prescribers who treat patients diagnosed with GAD to be to be considered. Programs focused on
psychoeducation explaining the EBP guidelines to treat patients with GAD and ways to
minimize prescribing benzodiazepines could bridge the health disparity gap among patients
diagnosed with GAD and using BZDs. According to the American Association of Colleges of
Nursing (AACN), one role of the DNP-prepared advance practice nurse is to become an
innovative leader in the transformation of the current health care system (AACN, 2004). The
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DNP prepared nurse must be prepared and ready to lead, collaborate and advocate with the goal
of improving patient and healthcare outcomes.
Quality and Safety
Prolonged use of benzodiazepine among persons with anxiety and related disorder may
exacerbate health conditions by leading to increased anxiety and increase risk for complications
including death (Hayhoe & Lee-Davey, 2018). This reinforces the need to de-escalate
benzodiazepine use. De-escalating the use of benzodiazepines for adults is crucial in concerted
health promotion initiatives to promote the appropriate use of the medication, prevent harm from
abuse, and improve patient outcomes (Suss & Oldani 2020). Healthcare providers particularly
nurse practitioners and physician assistant play a significant role in promoting proper use of and
in de-escalation among patients with anxiety who have misused the drug (Platt et al., 2021). This
is achieved by implementing evidenced based practice guidelines that will reduce potential for
benzodiazepine misuse and abuse.
In addition to psychoeducation on EBP guidelines to treat patients with anxiety,
healthcare providers are encouraged to routinely monitor patients at risk for benzodiazepine
misuse and educate them about different options to treat their anxiety (Bersani et al., 2017).
Adhering to evidence-based guidelines on appropriate screening protocol and benzodiazepine
safety monitoring would not only decrease benzodiazepine use but eventually save lives (Bersani
et al., 2017).
Education
Implementation of EBP guidelines leads to improving a quality of care and best outcomes
for the patient with generalized anxiety, reduces cost and disparity, empowers clinicians, and
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increases role satisfaction (Melnyk & Fineout-Overholt, 2015). Continuity of seeking and
implementing current best evidence practice is imperative to prevent outdated treatments for
patients diagnosed with GAD that will lead to poor patient outcomes. The DNP-prepared nurse
must continue to implement practice change projects, educate providers, patients and their
caregivers, advocate policy changes that sustains EBP change and embrace new evidence to
combat non-adherence. It will be beneficial for future work to recognize the role of
families/caregivers. Providing psychoeducation to the providers that treat patients with anxiety
on the need to include healthy lifestyle changes in the lives of patients prescribed
benzodiazepines and other anti-anxiety medications will be more effective than an individual
session.
Sustainability
Long term strategies are needed to sustain a project change. Upon completion of this EBP
change project, the PI and stakeholders at the implementation site was considering several
approaches to sustain the positive changes that were achieved. These approaches include the
addition of psychoeducational groups to treatment as usual for patients prescribed
benzodiazepines and anti-anxiety medications. Psychiatrists, APRNs, and Physician Assistants
(PA) at the clinical site recommended psychoeducational sessions about available treatments for
generalized anxiety to patients, and front office staff have been assigned to compile names for
the Licensed Clinical Social Workers (LCSW) who developed group sessions involving
prescribers as well. Participants who took part in the recently completed EBP change project
were given the opportunity to participate in educational sessions, with the goal of reinforcing
what was previously learned.
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Future Scholarship
Collaboration among a wide range of mental health providers is planned to engage a
larger number of participants and to implement future projects in a larger area of the community.
Poster presentations at professional organizations for mental health providers such as American
Psychiatric Nurses Association (APNA) Nevada chapter will be utilized to accomplish this goal.
Psychoeducational intervention based on EBP guidelines must be added to regular appointments
and incorporated into treatments for patients prescribed BZDs medications and alternative
treatments for GAD. Prescribers are more likely to adhere to EBP guidelines reference card if
they have a better understanding of GAD, options of treatments, and risks related to
benzodiazepine use.
Conclusion
The consequences of misusing benzodiazepines are dire. Utilizing psychoeducation
during treatment as usual can be an effective intervention in improving utilization of quick
reference cards as EBP guidelines for managing patients who suffer from anxiety.
Psychoeducational interventions are designed to impart knowledge on risks of benzodiazepine
misuse and choosing alternative medications and strategies to treat anxiety. The pre-test and
post-test data analysis among participants before and after the project intervention will reinforce
that psychoeducation positively impacts lifestyle changes among patients prescribed antianxiety
medications. Implementing the tenets of this project at the practice site as well as other
behavioral health sites could set new standards and eventually improve overall wellbeing for
patients diagnosed with generalized anxiety disorder.

47
References
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A.,
Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., Malizia, A., McCrone, P.,
Nabarro, D., O'Neill, C., Scott, J., van der Wee, N., & Wittchen, H. U. (2014).
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress
disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from
the British Association for Psychopharmacology. Journal of Psychopharmacology,
28(5), 403–439. https://doi.org/10.1177/0269881114525674
Balon, R., & Starcevic, V. (2020). Role of benzodiazepines in anxiety disorders. Advances in
Experimental Medicine and Biology, 5(3), 367-388. https://doi.org/10.1007/978-98132-9705-0_20
Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues
in Clinical Neuroscience, 19(2), 93-107.
https://dx.doi.org/10.31887%2FDCNS.2017.19.2%2Fbbandelow
Bathla, M., Singh, M., & Relan, P. (2016). Prevalence of anxiety and depressive symptoms
among patients with hypothyroidism. Indian Journal of Endocrinology and
Metabolism, 20(4), 468-474. https://dx.doi.org/10.4103%2F2230-8210.183476
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015).
Efficacy of treatments for anxiety disorders. International Clinical
Psychopharmacology, 30(4), 183-192.https://doi.org/10.1097/yic.0000000000000078
Bersani, F., Biondi, M., Coviello, M., Fagiolini, A., Majorana, M., Minichino, A., Coccanari
Foreni, M. (2017). Psychoeducational intervention focused on healthy living
improves psychopathological severity and lifestyle quality in psychiatric patients:

48
preliminary findings from a controlled study. Journal of Mental Health, 26(3), 271–
275. https://doi.org/10.1080/09638237.2017.1294741
Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse and
dependence. Australian Prescriber, 38(5), 152155. https://doi.org/10.18773/austprescr.2015.055
Carr, F., Tian, P., Chow, J., Guzak, J., Triscott, M., Sun, X., & Dobbs. B. (2019).
Deprescribing benzodiazepine among hospitalized older adults: quality improvement
initiative. BMJ Open Quality, 8(3). https://doi.10.1136/bmjoq-2018-000539
Charfi, N. (2017). Chronic benzodiazepine use in aged patients with depressive
disorder. https://doi.org/10.26226/morressier.5885d713d462b8028d891061
Conn, D. K., Hogan, D. B., Amdam, L., Cassidy, K. L., Cordell, P., Frank, C., Gardner, D.,
Goldhar, M., Ho, J. M., Kitamura, C., & Vasil, N. (2020). Canadian guidelines on
benzodiazepine receptor agonist use disorder among older adults. Canadian
Geriatrics Journal, 23(1), 116–122. https://doi.org/10.5770/cgj.23.419
Coury, J., Schneider, J. L., Rivelli, J. S., Petrik, A. F., Seibel, E., D'Agostini, B., Taplin, S. H.,
Green, B. B., & Coronado, G. D. (2017). Applying the Plan-Do-Study-Act (PDSA)
approach to a large pragmatic study involving safety net clinics. BMC Health Services
Research, 17(1), 411. https://doi.org/10.1186/s12913-017-2364-3
Davidson, J. R., Zhang, W., Connor, K. M., Ji, J., Jobson, K., Lecrubier, Y., McFarlane, A.
C., Newport, D. J., Nutt, D. J., Osser, D. N., Stein, D. J., Stowe, Z. N., Tajima, O., &
Versiani, M. (2010). A psychopharmacological treatment algorithm for GAD

49
(GAD). Journal of Psychopharmacology, 24(1), 3–26.
https://doi.org/10.1177/0269881108096505
Evans, K., Spiby, H., & Morrell, J. C. (2019). Non-pharmacological interventions to reduce
the symptoms of mild to moderate anxiety in pregnant women. A systematic review
and narrative synthesis of women’s views on the acceptability of and satisfaction with
interventions. Archives of Women's Mental Health, 23(1), 11-28.
https://doi.org/10.1007/s00737-018-0936-9
Faravelli, C., Rosi, S., & Truglia, E. (2019). Benzodiazepines. Anxiety Disorders, 8(4), 313338. https://doi.org/10.1002/9780470986844.ch17
Gautam, S., Jain, A., Gautam, M., Vahia, V. N., & Gautam, A. (2017). Clinical practice
guidelines for the management of generalized anxiety disorder (GAD) and panic
disorder (PD). Indian journal of psychiatry, 59(1), 67-73.
https://dx.doi.org/10.4103%2F0019-5545.196975
Hayhoe, B., & Lee-Davey, J. (2018). Tackling benzodiazepine misuse. British Medical
Journal, 362-365. https://www.bmj.com/content/362/bmj.k3208
Hirschtritt, M. E., Olfson, M., & Kroenke, K. (2021). Balancing the risks and benefits of
benzodiazepines. JAMA, 325(4), 347-348. https://doi.org/10.1001/jama.2020.22106
Jones. (2016). Benzodiazepine withdrawal. The International Handbook of Addiction
Behaviour, 108-112. https://doi.org/10.4324/9781315542355-25
Johnson, J., & Garvin, W. (2017). Advanced practice nurses: Developing a business plan for
an independent ambulatory clinical practice. Nursing Economic, 35(3), 126–141.
https://go.gale.com/ps/i.do?id=GALE%7CA502001257&sid=googleScholar&v=2.1

50
&it=r&linkaccess=abs&issn=07461739&p=AONE&sw=w&userGroupName=anon%
7E56b2bbf5
Lader, M. (2019). Benzodiazepines, anxiety and catecholamines. Anxiety and the Anxiety
Disorders, 77-84. https://doi.org/10.4324/9780203728215-6
Lembke, A., Papac, J., & Humphreys, K. (2018). Our other prescription drug problem. The New
England Journal of Medicine, 378(8), 693-695. https://doi.org/10.1176/appi.ps.201800321
Lewin, K., & Gold, M. (1999). The dynamics of group action. In M. Gold, M. Gold (Eds.), The
complete social scientist: A Kurt Lewin reader (pp. 285-291). American Psychological
Association.
Maust, D. T., Lin, L. A., & Blow, F. C. (2020). Benzodiazepine use and misuse among adults in
the United States. Psychiatric Services, 70(2), 97-106.
https://dx.doi.org/10.1176%2Fappi.ps.201800321
Olfson, M. (2016). The rise of primary care physicians in the provision of US mental health care.
Journal of Health Politics, Policy & Law, 41(4), 559–583.
https://doi.org/10.1215/03616878-3620821
Pascal, J., Shedden-Mora, M.C., & Lowe, B. (2017). Psychometric analysis of the Generalized
Anxiety Disorder scale (GAD-7) in primary care using modern item response theory.
PLOS. e0182162-e0182174. https://doi.org/10.1371/journal.pone.0182162
Peppin, J., Pergolizzi, J. V., Raffa, R. B., & Wright, S. L. (2020). The benzodiazepines crisis.
Oxford University Press, USA.
Platt, L. M., Whitburn, A. I., Platt-Koch, A. G., & Koch, R. L. (2016). Nonpharmacological
alternatives to benzodiazepine drugs for the treatment of anxiety in outpatient

51
populations: A literature review. Journal of Psychosocial Nursing and Mental Health
Services, 54(8), 35-42. https://doi.org/10.3928/02793695-20160725-07
Roy-Byrne P. (2015). Treatment-refractory anxiety; definition, risk factors, and treatment
challenges. Treatment of Affective Dysfunction in Challenging Contexts, 17(2), 191206. https://doi.org/10.31887/dcns.2015.17.2/proybyrne
Samardzic, J., & Svob Strac, D. (2016). Benzodiazepines and anxiety disorders: From
laboratory to clinic. New Developments in Anxiety Disorders.
https://doi.org/10.5772/64959
Schmitz A. (2016). Benzodiazepine use, misuse, and abuse: A review. The mental health
clinician, 6(3), 120–126. https://doi.org/10.9740/mhc.2016.05.120
School of Health and Related Research (ScHARR), University of Sheffield. (2004). Clinical
Guidelines for the Management of Anxiety: Management of Anxiety (Panic Disorder,
with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in
Primary, Secondary and Community Care. National Collaborating Centre for Primary
Care (UK).
Shinfuku M., Kishimoto T., Uchida H., Suzuki T., & Mimura M. (2019). Effectiveness and
safety of long-term benzodiazepine use in anxiety disorders: A systematic review and
meta-analysis. Int Clin Psychopharmacol, 34(5), 211-221.
https://doi.org/10.1097/yic.0000000000000276
Silberman, E., Balon, R., Starcevic, V., Shader, R., Cosci, F., Fava, G. A. & Sonino, N.
(2021). Benzodiazepines: it's time to return to the evidence. The British Journal of
Psychiatry, 218(3), 125-127. https://doi.org/10.1192/bjp.2020.164
Simon, N. M., Hofmann, S. G., Rosenfield, D., Hoeppner, S. S., Hoge, E. A., Bui, E., & Khalsa,

52
S. B. S. (2021). Efficacy of yoga vs cognitive behavioral therapy vs stress education for
the treatment of generalized anxiety disorder: a randomized clinical trial. JAMA
Psychiatry, 78(1), 13-20. https://doi.org/10.1001/jamapsychiatry.2020.2496
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018). Pharmacotherapy
for GAD in adult and pediatric patients: An evidence-based treatment review. Expert
Opinion on Pharmacotherapy, 19(10),
1057–1070. https://doi.org/10.1080/14656566.2018.1491966
Suss, T., & Oldani, M. (2020). Little helpers no more: A framework for collaborative
deprescribing of benzodiazepines in older adults. Journal of Psychosocial Nursing
and Mental Health Services, 58(1), 23-28. https://doi.org/10.3928/0279369520191218-05
Sapra, A., Bhandari, P., Sharma, S., Chanpura, T., & Lopp, L. (2020). Using generalized anxiety
disorder-2 (GAD-2) and GAD-7 in a primary care setting. Cureus, 12(5), e8224https://dx.doi.org/10.7759%2Fcureus.8224
The Agree Enterprise Trust. (2009). Appraisal of Guidelines for Research & Evaluation II.
https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manualand-23-item-Instrument-2009-Update-2017.pdf
Trivedi, R., Post, E., Sun, H., Pomerantz, A., Saxon, A., Piette, J., & Nelson, K. (2015).
Prevalence, comorbidity, and prognosis of mental health among US veterans. American
Journal of Public Health, 105(12), 2564–2569.
https://doi.org/10.2105/ajph.2015.302836
Tyrer, P. (2019). Why benzodiazepines are not going away. Advances in Psychiatric
Treatment, 18(4), 259-262. https://doi.org/10.1192/apt.bp.111.009209

53
Appendix A
Table 1. Hierarchy Table
Melnyk

Evidence 1

Evidence 2

Evidence 3

Evidence 4

Evidence 5

Evidence 6

Level

(Bandelow,

(Bandelow,

(Roy-Byrne,

(Platt, et al,

(Carr, et al.,

( Liebrenz, et

et al., 2017)

et al., 2015)

et al., 2015).

2016)

2019).

al, 2015)

I

II

X

X

X

III

IV

X

V

VI

VII

X

X

54
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BAI = Beck Anxiety Inventory; CALM = Coordinated Anxiety Learning and Management; DV =
dependent variable; EPDS = Edinburgh Postnatal Depression Scale; GAD-2 = GAD–2 items; GAD-7=
GAD–7 items; AHM-A- Hamilton anxiety scale; IV=independent variable; NR= narrative synthesis; MA
= meta-analysis; PDQ=Prenatal Distress Questionnaire; PHQ-9=Patient Health Questionnaire–9; ICD10= International Classification of Diseases; PSWQ =Penn State Worry Questionnaire; RCT =
randomized controlled study; SR = systematic review; QS = qualitative study
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Appendix B
Theoretical Conceptual Framework

Kurt Lewin s Change Theory
Stages
Unfreeze
Change
Refreeze

Lewin, K.,

old, M. (1999)

Figure 1: Model for Improvement
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Appendix C
Demographic & Pre-Intervention Form
Demographic form
Question #

Question

Inclusion Rationale

1

Q: What is your age?

To identify generational

Choices:

learning preference

21-29 yo
30-39 yo
40-49 yo
50-59 yo
60or older
2

Q: Which type of degree do

To distinguish educational

you have ?

paths

Choices:
APRN
PA
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3

Q: What is your population of To distinguish within
focus?
Choices:

population that is being
treated

Family
Adult Gerontology
Pediatrics
Other
4

Q: In your clinical training,

To assess barriers in

have you encountered barriers prescribing benzodiazepines
in learning how to prescribe
benzodiazepines?
Choices:
Yes
No
If yes, check all that apply:
No access to guidelines
Personal preferences
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5

Q: When you make choices to To distinguish choices in
prescribe medications for

prescribing medications

GAD, what do you primarily
base your choices on?
Choices:
Current patient’s medications
Personal preferences
Other
6

Q: How often are you using

To determinate if guidelines

guidelines for Generalized

are used

Anxiety Treatment?
Choices:
Always
Never
Sometimes
7

Q: What tools do you use in
diagnosing GAD?
Choices:

To assess what tool is used

66
Beck Anxiety Inventory
(BAI)
Penn State Worry
Questionnaire (PSWQ)
GAD 7 (GAD-7)
8

What are the challenges when

To allow clinicians to express

prescribing medications to

their challenges in treating

treat patients with GAD?

patient with GAD

Describe
9

What are the most common

To determinate strategies that

strategies do you use in

are used in treatment of GAD

treating patients with GAD?
Scale 1-5
Choices:
CTB
Meditation
Benzodiazepines
Anxiolytics
SSRIs
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Appendix D
GAD-7 Form
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Appendix E
Chart Review
Provider:
Participants

Offered a non- Appropriate

GAD—7

pharmacologic Medication

Baseline

therapy

Patient_ID 1
Patient_ID 2
Patient_ID 3
Patient_ID 4
Patient_ID 5
Patient_ID 6

Therapy

(Goal: ___)

GAD-7
Post

Number of
Benzo Rx
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Appendix F
Reference Card

The first-line treatment and gold standard for treating anxiety is CBT
Medications: (SSRI) escitalopram, paroxetine, sertraline, (SNRIs) venlafaxine, duloxetine
2nd line gad maintenance: buspirone (BuSpar)

3rd line: benzodiazepines

Alternatives for GAD maintenance: hydroxyzine, pregabalin, quetiapine

tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs),atypical antipsychotic medications, other medications
used off-label, such as beta-blockers
Lifestyle changes: Exercise, breathing techniques, meditation and mindfulness, restful sleep, avoid anxiety triggers (reduce or stop caffeine,
alcohol, tobacco and other substances)

How is GAD diagnosed? DSMV-5 symptoms, difficult to control worry over 6 months: restlessness, easily fatigued, difficult concentration,
irritable, muscle tension, sleep disturbance

Acute GAD treatment: be
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Appendix G
Statement of Mutual Agreement
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Appendix H
Recruitment Flyer
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Appendix I
Weekly Agenda for De-escalating Benzodiazepine Use Project
Weekly Agenda

Topics

Week 1

EBP guidelines and GAD treatment, GAD 7,
DSM V GAD categories and proper dx, first
line GAD tx, therapies, de-escalating use of
benzodiazepine

Week 2

Reporting data from appointment
Discussion

Week 3

Reporting data from appointment
Discussion

Week 4

Reporting data from appointment
Discussion

Week 5

Reporting data from appointment
Discussion

Week 6

Reporting data from appointment
Discussion

Week 7

Reporting data from appointment
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Discussion
Week 8

Chart Review
Evaluation

